Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc. Class A Common Stock represents ownership in Ironwood Pharmaceuticals, Inc., a biotechnology company focused on developing and commercializing therapies for gastrointestinal disorders and rare diseases. Its current business centers on human therapeutics, with an emphasis on medicines for conditions such as irritable bowel syndrome with constipation and chronic idiopathic constipation. The company’s commercial portfolio is anchored by LINZESS, a treatment used in gastrointestinal care, while its broader pipeline reflects ongoing work in GI-focused and other specialty medicine programs. Headquartered in Boston, Massachusetts, Ironwood serves patients, healthcare providers, and commercial partners through product development, marketing, and lifecycle management in the pharmaceutical sector. As a publicly traded healthcare company, it plays a role in the specialized drug market by addressing areas of significant unmet medical need.